Symmetric dimethylarginine (SDMA) is raised in women with polycystic ovary syndrome: a pilot study.

NMUH Staff Publications

31

<div class="abstr" style="margin: 1em auto auto; font-family: arial, helvetica, clean, sans-serif; font-size: 13px; line-height: 17.999801635742188px;"><div><p style="margin: 0px 0px 0.5em;">Polycystic ovary syndrome (PCOS) is associated with endothelial dysfunction, which may be caused by elevated levels of asymmetric dimethylarginine (ADMA). ADMA reduces nitric oxide production in diabetes mellitus, hypertension and renal failure. <span class="highlight">Symmetric dimethylarginine</span> (SDMA) is a stereoisomer produced alongside ADMA, and has recently been described as a risk factor for cardiovascular events. In this cross-sectional study based in a teaching hospital, 16 women with PCOS were recruited alongside 15 healthy controls, and fasting venous blood samples were obtained. Renal function was measured, and ADMA and SDMA were analysed using a high-performance liquid chromatography method. After controlling for BMI, mean ADMA and SDMA levels in women with PCOS were higher than in controls (p = 0.036 and p = 0.030, respectively). Renal function was not different between the two groups (p = 0.152). Women with PCOS have raised levels of SDMA, a molecule implicated in endothelial dysfunction and long-term cardiovascular risk.</p></div></div>